DanielsK, AbmaJC. Current contraceptive status among women aged 15–49: United States, 2017–2019. NCHS Data Brief, 2020(388):1–8.
2.
LaurentMR, HammondGL, BloklandM, et al.Sex hormone-binding globulin regulation of androgen bioactivity in vivo: Validation of the free hormone hypothesis. Sci Rep, 2016; 6:35539.
ZhangN, ShonJ, KimMJ, et al.Role of CYP3A in oral contraceptives clearance. Clin Transl Sci, 2018; 11(3):251–260.
5.
FotherbyK.Interactions with oral contraceptives. Am J Obstet Gynecol, 1990; 163(6 Pt 2):2153–2159.
6.
SchallerSJ, FinkH. Sugammadex as a reversal agent for neuromuscular block: An evidence-based review. Core Evid, 2013; 8:57–67.
7.
LazorwitzA, DindingerE, AguirreN, et al.Pre- and post-operative counseling for women on hormonal contraceptives receiving sugammadex at an academic hospital. J Anesth, 2020; 34(2):294–297.
8.
RichardsonMG, RaymondBL. Sugammadex administration in pregnant women and in women of reproductive potential: A narrative review. Anesth Analg, 2020; 130(6):1628–1637.
Society for Obstetric Anesthesia and Perinatology Statement on Sugammadex during pregnancy and lactation. [Internet]. Available from: soap.org/wp-content/uploads/2019/06/SOAP_Statement_Sugammadex_During_Pregnancy_Lactation_APPROVED.pdf [Last accessed: November10, 2022].
11.
DwanRL, RaymondBL, RichardsonMG. Unanticipated consequences of switching to sugammadex: Anesthesia provider survey on the hormone contraceptive drug interaction. Anesth Analg, 2021; 133(4):958–966.
12.
RitchieMK, KohliA.Aprepitant. StatPearls Publishing LLC: Treasure Island, FL, USA; 2022.
13.
BailardN, RebelloE. Aprepitant and fosaprepitant decrease the effectiveness of hormonal contraceptives. Br J Clin Pharmacol, 2018; 84(3):602–603.
14.
AaproMS, WalkoCM. Aprepitant: Drug-drug interactions in perspective. Ann Oncol, 2010; 21(12):2316–2323.
WangB, SanchezRI, FranklinRB, et al.The involvement of CYP3A4 and CYP2C9 in the metabolism of 17 alpha-ethinylestradiol. Drug Metab Dispos, 2004; 32(11):1209–1212.
